grant
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers
Organization STATE UNIVERSITY OF NEW YORK AT BUFFALOLocation AMHERST, UNITED STATESPosted 10 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025AbateAddressAndrogen ReceptorAnimalsArchitectureAssayAutomobile DrivingBackBasal Transcription FactorBasal transcription factor genesBindingBioassayBiological AssayBiologyCancer BurdenCell BodyCell Communication and SignalingCell SignalingCellsChIP SequencingChIP-seqChIPseqChromatinClinicClinicalClinical ManagementCombined Modality TherapyDNADataDeoxyribonucleic AcidDiseaseDisorderDorsumELF3ELF3 geneEPR-1ERT geneERT proteinESE-1ESXEarly-Stage Clinical TrialsEngineering / ArchitectureEnhancersExposure toGene ExpressionGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGenetic TranscriptionGoalsIntracellular Communication and SignalingIntratumoral heterogeneityKnowledgeMalignant CellMalignant neoplasm of prostateMalignant prostatic tumorMediatingModelingMolecularMolecular InteractionMultimodal TherapyMultimodal TreatmentNR1B1National Cancer BurdenNeighborhoodsOrganoidsPDX modelPathway interactionsPatient derived xenograftPatientsPatternPhase 1 Clinical TrialsPhase 2 Clinical TrialsPhase I Clinical TrialsPhase II Clinical TrialsPhenotypePhysiciansPlayPopulationPre-Clinical ModelPreclinical ModelsPreclinical dataProstate CAProstate CancerProstate malignancyProteinsProteomicsRARARARA geneRNA ExpressionRNA SeqRNA sequencingRNAseqReportingResistanceResistance developmentResistant developmentResolutionRetinoic Acid Receptor Alpha GeneRoleSYS-TXScientistSignal TransductionSignal Transduction SystemsSignalingSystemic TherapyTestingTherapeuticToxicologyTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTranslatingTumor CellXtandiabirateroneaddictionaddictive disorderadvanced diseaseadvanced illnessadvanced prostate cancerandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerantagonismantagonistbiological signal transductioncancer cellcastration resistant CaPcastration resistant PCacastration resistant prostate cancerchromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingcombination therapycombined modality treatmentcombined treatmentdeveloping resistancedrivingdrug discoveryeffective therapyeffective treatmentenzalutamideheterogeneity in tumorshigh riskhormone refractory prostate cancerimprovedimproved outcomeinterestintra-tumoral heterogeneityintratumor heterogeneitymenmulti-modal therapymulti-modal treatmentmulti-modalitymultimodalitymultiomicsmultiple omicsneoplastic cellnoveloptimal therapiesoptimal treatmentspanomicspathwaypatient derived xenograft modelpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespharmacologicphase I protocolphase II protocolpre-clinical trialpreclinical findingspreclinical informationpreclinical trialpromoterpromotorprostate cancer resistant to androgenprotein expressionreceptor expressionrecruitrelapse patientsresistance to therapyresistantresistant to therapyresolutionssocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapeutic targettherapy resistanttranscription factortranscriptome sequencingtranscriptomic sequencingtranscriptomicstreatment resistancetreatment strategytumortumor heterogeneity
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY (ABSTRACT)
Androgen receptor (AR) targeted therapies such as abiraterone, enzalutamide, apalutamide, and darolutamide are effective
treatments for patients with advanced castrate-resistant prostate cancer (CRPC). However, resistance to these therapies
represents a significant hurdle in the clinical management of advanced CRPC.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click